Research view
Switch to patient viewColorectal cancer: trials that stopped early
Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Reason given in the registry “company development strategy adjustment”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2026.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
- Registry record
- NCT05497336
Terminated
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
Reason given in the registry “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.
- Ended
- Apr 2025
- Phase
- Phase 1/2
- Run by
- NextCure, Inc.
- Registry record
- NCT05572684
Withdrawn
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Reason given in the registry “Study tracer is currently unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Aug 2026.
- Ended
- Aug 2026
- Phase
- Phase 1
- Run by
- Memorial Sloan Kettering Cancer Center
- Registry record
- NCT05737615
Withdrawn
Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy
Reason given in the registry “protocol change”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Aug 2026.
- Ended
- Dec 2025
- Run by
- Kyungpook National University Hospital
- Registry record
- NCT03503071
Withdrawn
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Reason given in the registry “The study was withdrawn before participant enrollment because the research team decided not to initiate the study after reassessing its feasibility.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Aug 2026.
- Ended
- May 2024
- Run by
- Fudan University
- Registry record
- NCT06221423
Terminated
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Jul 2026.
- Ended
- Jul 2026
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT03203525
Terminated
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
Reason given in the registry “Lack of financial support”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.
- Ended
- Mar 2026
- Run by
- Henry Ford Health System
- Registry record
- NCT05526079
Terminated
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Reason given in the registry “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.
- Ended
- May 2025
- Phase
- Phase 1/2
- Run by
- NuCana plc
- Registry record
- NCT05714553
Terminated
Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders
Reason given in the registry “Lack of financial support”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.
- Ended
- Apr 2025
- Run by
- Henry Ford Health System
- Registry record
- NCT03941366
Terminated
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Reason given in the registry “Pharmaceutical Sponsor discontinued trial financial support”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Jul 2026.
- Ended
- Jul 2026
- Phase
- Phase 3
- Run by
- Canadian Cancer Trials Group
- Registry record
- NCT07152821
Suspended
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Reason given in the registry “Drugs unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.
- Phase
- Phase 1
- Run by
- David Wald
- Registry record
- NCT05400122
Terminated
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Reason given in the registry “No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jul 2026.
- Ended
- Aug 2025
- Phase
- Phase 1/2
- Run by
- TCR2 Therapeutics
- Registry record
- NCT05451849
Withdrawn
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
Reason given in the registry “The sponsor requested to terminate the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.
- Ended
- Apr 2024
- Phase
- Phase 1/2
- Run by
- Chongqing Precision Biotech Co., Ltd
- Registry record
- NCT04348643
Withdrawn
The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects With Colorectal Cancer-related Fatigue
Reason given in the registry “Insufficient recruitment”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2026.
- Ended
- Feb 2025
- Run by
- Mycotech Pharma AS
- Registry record
- NCT06599710
Terminated
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Reason given in the registry “The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Jul 2026.
- Ended
- Apr 2026
- Phase
- Phase 1
- Run by
- BeOne Medicines
- Registry record
- NCT06585488
Terminated
A Study of SGN-MesoC2 in Advanced Solid Tumors
Reason given in the registry “The trial was terminated for strategic reasons. The decision was not based on any safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Jul 2026.
- Ended
- May 2026
- Phase
- Phase 1
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
- Registry record
- NCT06466187
Terminated
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Reason given in the registry “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Jul 2026.
- Ended
- Jun 2025
- Phase
- Phase 1/2
- Run by
- Syndax Pharmaceuticals
- Registry record
- NCT05731947
Suspended
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
Reason given in the registry “For internal interim analysis”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2026.
- Phase
- Phase 1
- Run by
- University of California, Davis
- Registry record
- NCT05967533
Terminated
Use of Alternative and Complementary Medicine by Colorectal Cancer Patients
Reason given in the registry “Not enough awnser in the qualitative study”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jun 2026.
- Ended
- Apr 2026
- Run by
- University Hospital, Limoges
- Registry record
- NCT06779669
Terminated
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
Reason given in the registry “Toxicity in phase 1”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jun 2026.
- Ended
- Nov 2025
- Phase
- Phase 1
- Run by
- University of Iowa
- Registry record
- NCT04926324
Terminated
A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer
Reason given in the registry “funding withdrawal”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Jun 2026.
- Ended
- Jun 2026
- Phase
- Phase 2
- Run by
- University of Southampton
- Registry record
- NCT06692959
Terminated
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Reason given in the registry “Development discontinued.”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Jun 2026.
- Ended
- May 2026
- Phase
- Phase 1
- Run by
- Day One Biopharmaceuticals, Inc.
- Registry record
- NCT05514717
Terminated
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Reason given in the registry “The study was closed due to accrual.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2026.
- Ended
- Apr 2026
- Phase
- Phase 2
- Run by
- Northwestern University
- Registry record
- NCT05576896
Withdrawn
The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.
Reason given in the registry “Sponsor decided not to move forward with the site.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jun 2026.
- Run by
- University of Colorado, Denver
- Registry record
- NCT07292285
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Reason given in the registry “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04458259
Terminated
PF-07284892 in Participants With Advanced Solid Tumors
Reason given in the registry “The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.
- Ended
- Jun 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04800822
Withdrawn
Precision Nursing vs Conventional Care in Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial
Reason given in the registry “The trial was withdrawn before participant enrollment; no subjects were recruited and no data were collected.”
Quoted unchanged from ClinicalTrials.gov; record updated 29 May 2026.
- Ended
- May 2026
- Run by
- Jiangsu Cancer Institute & Hospital
- Registry record
- NCT07413510
Withdrawn
Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
Reason given in the registry “Due to corporate strategic adjustment.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2026.
- Ended
- Mar 2026
- Run by
- Guangzhou Bio-gene Technology Co., Ltd
- Registry record
- NCT07152210
Terminated
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Reason given in the registry “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 22 May 2026.
- Ended
- May 2026
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT06704724
Suspended
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
Reason given in the registry “Lack of treatment, sponsor decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.
- Phase
- Phase 2
- Run by
- UNICANCER
- Registry record
- NCT03722680
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.